Development of a new biochip array for APOE4 classification from plasma samples using immunoassay-based methods

What is it about?

APOE4 is the major genetic risk factor in Alzheimer's disease and plays a role in other (neuro)degenerative disorders. Therefore, we developed a novel, chemiluminescent multi-immunoassay platform using Biochip Array Technology to simultaneously detect APOE4 and total APOE levels in plasma. Two research sites in Austria and Ireland determined the null, heterozygous or homozygous APOE4 status by means of APOE4 to total APOE ratio in 170 and 262 samples, respectively. 100% accuracy was achieved. The new biochip may be extended by incorporating quantitative protein biomarker arrays capable of analyzing disease stages, which makes it a superior alternative to PCR-based APOE genotyping.

Featured Image